PRMT5 and acute lymphoblastic leukemia: As a result, the NDRG2 low-expressing T-ALL cell lines exhibited significantly decreased expression of AKT and NEMO, with cell growth suppressed by treatment with the PRMT5 inhibitors HLCL61 or CMP5 compared with the parental and shluc T-ALL cell lines (Figure 4B–D and Supplementary Figure S4A).